Emily Aspasia Karanges

Emily Aspasia Karanges

Auto-generated profile, based on publicly available information

Emily Aspasia Karanges

The University of Melbourne Centre for Youth Mental Health

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
EKEmily A. Karanges
Emily A. Karanges
NBNicholas A. Buckley
Nicholas A. Buckley
JBJonathan Brett
Jonathan Brett
BBBianca Blanch
Bianca Blanch
MLMelisa Litchfield
Melisa Litchfield
DPDr Sallie Pearson
Dr Sallie Pearson

19 October 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
NGNatasa Gisev
Natasa Gisev
DPDr Sallie Pearson
Dr Sallie Pearson
EKEmily A. Karanges
Emily A. Karanges
BLBriony Larance
Briony Larance
NBNicholas A. Buckley
Nicholas A. Buckley
LDLouisa Degenhardt
Louisa Degenhardt

19 January 2021 in International Journal of Population Data Science
Verified
Journal Article
Open access
PDF file
JCJuliana Costa
Juliana Costa
CBClaudia Bruno
Claudia Bruno
ASAndrea L Schaffer
Andrea L Schaffer
SRSmriti Raichand
Smriti Raichand
EKEmily A Karanges
Emily A Karanges
DPDr Sallie Pearson
Dr Sallie Pearson
Objective A wealth of data is generated through Australia’s universal health care arrangements. However, use of these data has been hampered by different federal and state legislation, privacy concerns and challenges in linking data across jurisdictions. A series of data reforms have been touted to increase population health research capacity in Australia, including pharmacoepidemiology research. Here we catalogued research leveraging Australia’s Pharmaceutical Benefits Scheme (PBS) data (2014–2018) and discussed these outputs in the context of previously implemented and new data reforms. Methods We conducted a systematic review of population-based studies using PBS dispensing claims. Independent reviewers screened abstracts of 4,996 articles and 310 full-text manuscripts. We characterised publications according to study population, analytical approach, data sources used, aims and medicines focus. Results We identified 180 studies; 133 used individual-level data, 70 linked PBS dispensing claims with other health data (66 across jurisdictions). Studies using individual-level data focussed on Australians receiving government benefits (87 studies) rather than all PBS-eligible persons. 63 studies examined clinician or patient practices and 33 examined exposure-outcome relationships (27 evaluated medicines safety, 6 evaluated effectiveness). Medicines acting on the nervous and cardiovascular system account for the greatest volume of PBS medicines dispensed and were the most commonly studied (67 and 40 studies, respectively). Antineoplastic and immunomodulating agents account for approximately one third of PBS expenditure but represented only 10% of studies in this review. Conclusions The studies in this review represent more than a third of all population-based pharmacoepidemiology research published in the last three decades in Australia. Recent data reforms have contributed to this escalating output. However, studies are concentrated among specific subpopulations and medicines classes, and there remains a limited understanding of population benefits and harms derived from medicines use. The current draft Data Availability and Transparency legislation should further bolster efforts in population health research.

20 August 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
BBBehrad Behdarvand
Behrad Behdarvand
EKEmily A Karanges
Emily A Karanges
LBLisa Bero
Lisa Bero
Objectives To describe the nature, frequency and content of non-vitamin K oral anticoagulant (NOAC)-related events for healthcare professionals sponsored by the manufacturers of the NOACs in Australia. A secondary objective is to compare these data to the rate of dispensing of the NOACs in Australia. Design and setting This cross-sectional study examined consolidated data from publicly available Australian pharmaceutical industry transparency reports from October 2011 to September 2015 on NOAC-related educational events. Data from April 2011 to June 2016 on NOAC dispensing, subsidised under Australia’s Pharmaceutical Benefits Scheme (PBS), were obtained from the Department of Health and the Department of Human Services. Main outcome measures Characteristics of NOAC-related educational events including costs (in Australian dollars, $A), numbers of events, information on healthcare professional attendees and content of events; and NOAC dispensing rates. Results During the study period, there were 2797 NOAC-related events, costing manufacturers a total of $A10 578 745. Total expenditure for meals and beverages at all events was $A4 238 962. Events were predominantly attended by general practitioners (42%, 1174/2797), cardiologists (35%, 977/2797) and haematologists (23%, 635/2797). About 48% (1347/2797) of events were held in non-clinical settings, mainly restaurants, bars and cafes. Around 55% (1551/2797) of events consisted of either conferences, meetings or seminars. The analysis of the content presented at two events detected promotion of NOACs for unapproved indications, an emphasis on a favourable benefit/harm profile, and that all speakers had close ties with the manufacturers of the NOACs. Following PBS listings relevant to each NOAC, the numbers of events related to that NOAC and the prescribing of that NOAC increased. Conclusions Our findings suggest that the substantial investment in NOAC-related events made by four pharmaceutical companies had a promotional purpose. Healthcare professionals should seek independent information on newly subsidised medicines from, for example, government agencies or drug bulletins.

13 November 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
ASAndrea L. Schaffer
Andrea L. Schaffer
EKEmily A. Karanges
Emily A. Karanges
NBNicholas A. Buckley
Nicholas A. Buckley
AWAndrew Wilson
Andrew Wilson
LDLouisa Degenhardt
Louisa Degenhardt
SPSallie‐Anne Pearson
Sallie‐Anne Pearson

31 August 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
EKEmily Aspasia Karanges
Emily Aspasia Karanges
CNConrad Nangla
Conrad Nangla
LPLisa Parker
Lisa Parker
AFAlice Fabbri
Alice Fabbri
CFCynthia Farquhar
Cynthia Farquhar
LBLisa Bero
Lisa Bero
Objectives To investigate the extent and nature of pharmaceutical industry payments related to fertility and assisted reproduction in Australia. Design and setting This retrospective observational study employed four databases compiled from publicly available pharmaceutical industry transparency reports on educational event sponsorship (October 2011–April 2018), payments to healthcare professionals (October 2015–April 2018) and patient group support (January 2013–December 2017). Analyses were restricted to fertility-related payments by two major manufacturers of fertility medicines in Australia: Merck Serono and Merck, Sharp and Dohme (MSD). Primary and secondary outcome measures Descriptive statistics on fertility-related payments and other transfers of value (counts, total and median costs in Australian dollars) for educational events and to healthcare professionals and patient groups. Results Between October 2011 and April 2018, Merck Serono and MSD spent $A4 522 263 on 970 fertility-related events for healthcare professionals, including doctors, nurses and fertility scientists. 56.8% (551/970) events were held by fertility clinics and 29.3% (284/970) by professional medical associations. Between October 2015 and April 2018, Merck Serono spent $A403 800 across 177 payments to 118 fertility healthcare professionals, predominantly for educational event attendance. Recipients included obstetricians and gynaecologists (76.3% of payments, 135/177), nurses (11.3%, 20/177) and embryologists/fertility scientists (9.6%, 17/117). The highest paid healthcare professionals held leadership positions in major fertility clinics. Merck Serono provided $A662 850 to fertility-related patient groups for advocacy and education (January 2013–December 2017). Conclusions The pharmaceutical industry sponsored a broad range of fertility clinicians and organisations, including doctors, nurses, embryologists, professional medical organisations, fertility clinics and patient groups. This sponsorship may contribute to the overuse of fertility services.